ENOB CV 11
Alternative Names: ENOB-CV-11Latest Information Update: 28 Jul 2025
At a glance
- Originator G-Tech Bio
 - Developer Renovaro Biosciences
 - Class COVID-19 vaccines; RNA vaccines; Synthetic vaccines
 - Mechanism of Action Apoptosis stimulants; Immunostimulants
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- No development reported COVID 2019 infections
 
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Inhalation)
 - 09 Aug 2023 Enochian BioSciences is now called Renovaro Biosciences
 - 21 Jun 2021 Enochain Bioscience entered a licensing agreement with G Tech Bio, LLC and Seraph Research Institute for the treatment of COVID-2019 infections (Enochian Bioscience pipeline June 2021)